Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function
Insurers Promise to Speed Up Delays in Health Care Approvals
By I. Edwards HealthDay ReporterWEDNESDAY, June 25, 2025 (HealthDay News) — Getting approval from your insurance company before a procedure or treatment may soon get a little easier.U.S. Health and …
Differences in Life Expectancy Underestimated for Indigenous Americans
Life expectancy of self-identified AI/AN individuals is about 73 years, which is several years less than U.S.-wide average
ADA: Weight Loss, Type 2 Diabetes Remission Up With Replacing Diet Drinks With Water
Greater weight loss and more diabetes remission seen among adult women with overweight, obesity and T2D
Mild Obstructive Sleep Apnea More Common in Female Athletes Than Expected
Mild OSA present in 25 percent of female collegiate athletes in study
Quality Improvement Initiative Ups Adherence to Medical Therapy for Heart Failure
Defect-free quadruple medication therapy significantly improved at discharge, 30 days in patients with heart failure with reduced ejection fraction
Hypertension Is Most Common Chronic Condition in People Aged 85 Years and Older
Overall, 7.4 percent of adults aged 85 years and older reported no chronic conditions, 37.3 percent reported four or more
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
Incidence rates of composite of death, MI, stroke were lower, but not significantly so, for patients treated with semaglutide
Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug
By I. Edwards HealthDay ReporterWEDNESDAY, June 18, 2025 (HealthDay News) — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront.The deal gives Lilly …
FDA Offers Speedier Approvals to Drug Companies Aligning With ‘National Priorities’
Agency is offering vouchers to some drug manufacturers to shorten review time for final drug applications